Roche Pharmaceuticals: $50 billion U.S. investment plan threatened by Trump's drug price cuts.

Swiss pharmaceutical group Roche said on Wednesday that the drug pricing executive order signed by US President Trump could jeopardize the company's $50 billion investment plan in the US. The executive order, signed on Monday, requires pharmaceutical companies to lower the prices of brand-name drugs to match those in other wealthy countries. Analysts and legal experts believe that this policy will be difficult to implement. Roche stated in a press release, "If this executive order goes into effect, there will be doubts about whether Roche can fulfill its previously announced major investment commitments in the US." The company also stated that it expects the executive order will not impact its business by 2025, and it will continue to communicate with the Trump administration and Congress.